GSD Stock Chart & Stats
C$9.10
C$0.75(8.82%)
At close: 4:00 PM EDT
C$9.10
C$0.75(8.82%)
Day’s Range― - ―
52-Week RangeC$5.10 - C$15.00
Previous CloseN/A
Volume404.00
Average Volume (3M)1.92K
Market Cap
C$23.98M
Enterprise ValueC$32.37
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding2,780,866
10 Day Avg. Volume1,012
30 Day Avg. Volume1,916
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Devonian Health Group News
GSD FAQ
What was Devonian Health Group, Inc.’s price range in the past 12 months?
Devonian Health Group, Inc. lowest stock price was C$5.10 and its highest was C$15.00 in the past 12 months.
What is Devonian Health Group, Inc.’s market cap?
Devonian Health Group, Inc.’s market cap is C$23.98M.
When is Devonian Health Group, Inc.’s upcoming earnings report date?
Devonian Health Group, Inc.’s upcoming earnings report date is Dec 02, 2026 which is in 74 days.
How were Devonian Health Group, Inc.’s earnings last quarter?
Devonian Health Group, Inc. released its earnings results on Jun 29, 2026. The company reported -C$0.701 earnings per share for the quarter.
Is Devonian Health Group, Inc. overvalued?
According to Wall Street analysts Devonian Health Group, Inc.’s price is currently Overvalued.
Does Devonian Health Group, Inc. pay dividends?
Devonian Health Group, Inc. does not currently pay dividends.
What is Devonian Health Group, Inc.’s EPS estimate?
Devonian Health Group, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Devonian Health Group, Inc. have?
Devonian Health Group, Inc. has 2,780,866 shares outstanding.
What happened to Devonian Health Group, Inc.’s price movement after its last earnings report?
Devonian Health Group, Inc. reported an EPS of -C$0.701 in its last earnings report. Following the earnings report the stock price went down -12%.
Which hedge fund is a major shareholder of Devonian Health Group, Inc.?
Currently, no hedge funds are holding shares in TSE:GSD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Devonian Health Group, Inc.
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs. It offers therapeutic and cosmeceutical products. Its drug candidate, Thykamine product is issued from Devonian’s SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The company was founded by Andre P. Boulet on March 27, 2015 and is headquartered in Montmagny, Canada.
Technical Analysis
Wesana Health Holdings Inc
―
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―